AcelRx Pharmaceuticals Inc.

1.20-0.0800-6.25%Vol 1.91M1Y Perf -5.47%
Apr 16th, 2021 16:00 DELAYED
BID1.21 ASK1.22
Open1.27 Previous Close1.28
Pre-Market- After-Market1.22
 - -  0.02 1.67%
Target Price
6.67 
Analyst Rating
Strong Buy 1.00
Potential %
455.83 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap142.74M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
9.84 
Earnings Date
10th May 2021

Today's Price Range

1.201.27

52W Range

1.012.94

5 Year PE Ratio Range

-4.10-3.30

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-14.29%
1 Month
-36.84%
3 Months
-42.31%
6 Months
-36.51%
1 Year
-5.47%
3 Years
-50.00%
5 Years
-68.50%
10 Years
-61.90%

TickerPriceChg.Chg.%
ACRX1.20-0.0800-6.25
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.12-0.1016.67
Q03 2020-0.07-0.10-42.86
Q02 2020-0.14-0.0842.86
Q01 2020-0.15-0.20-33.33
Q04 2019-0.22-0.1818.18
Q03 2019-0.23-0.1630.43
Q02 2019-0.23-0.1630.43
Q01 2019-0.23-0.1726.09
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.0811.11Positive
6/2021 QR-0.08-33.33Negative
12/2021 FY-0.27-42.11Negative
12/2022 FY0.10-58.33Negative
Next Report Date10th May 2021
Estimated EPS Next Report-0.08
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume1.91M
Shares Outstanding118.95M
Trades Count5.68K
Dollar Volume5.57M
Avg. Volume5.62M
Avg. Weekly Volume1.80M
Avg. Monthly Volume2.08M
Avg. Quarterly Volume5.12M

AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) stock closed at 1.2 per share at the end of the most recent trading day (a -6.25% change compared to the prior day closing price) with a volume of 1.92M shares and market capitalization of 142.74M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 54 people. AcelRx Pharmaceuticals Inc. CEO is Vincent J. Angotti.

The one-year performance of AcelRx Pharmaceuticals Inc. stock is -5.47%, while year-to-date (YTD) performance is -3.23%. ACRX stock has a five-year performance of -68.5%. Its 52-week range is between 1.01 and 2.94, which gives ACRX stock a 52-week price range ratio of 9.84%

AcelRx Pharmaceuticals Inc. currently has a PE ratio of -3.10, a price-to-book (PB) ratio of 71.81, a price-to-sale (PS) ratio of 33.11, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -48.72%, a ROC of -% and a ROE of 80.08%. The company’s profit margin is -%, its EBITDA margin is -812.10%, and its revenue ttm is $5.03 Million , which makes it $0.04 revenue per share.

Of the last four earnings reports from AcelRx Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.08 for the next earnings report. AcelRx Pharmaceuticals Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for AcelRx Pharmaceuticals Inc. is Strong Buy (1), with a target price of $6.67, which is +455.83% compared to the current price. The earnings rating for AcelRx Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AcelRx Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AcelRx Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.45, ATR14 : 0.18, CCI20 : -155.32, Chaikin Money Flow : -0.23, MACD : -0.21, Money Flow Index : 19.40, ROC : -25.47, RSI : 41.62, STOCH (14,3) : 0.00, STOCH RSI : 0.15, UO : 31.45, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AcelRx Pharmaceuticals Inc. in the last 12-months were: Adrian Adams (Buy at a value of $128 900), Vincent J. Angotti (Buy at a value of $10 035)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

AcelRx Pharmaceuticals Inc.

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system) SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for the reduction of moderate-to-severe acute pain in medically supervised settings.

CEO: Vincent J. Angotti

Telephone: +1 650 216-3500

Address: 351 Galveston Drive, Redwood City 94063, CA, US

Number of employees: 54

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

63%37%

Bearish Bullish

63%38%

Bearish Bullish

59%41%

News

Stocktwits